➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Express Scripts
Merck
Colorcon
Boehringer Ingelheim

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,525,104

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,525,104
Title:Methods for direct biomolecule identification by matrix-assisted laser desorption ionization (MALDI) mass spectrometry
Abstract: The present invention relates to the use of post source decay (PSD) or collision induced dissociation (CID) direct tissue (DT) MALDI-TOF or DT-MALDI-TOF-TOF mass spectrographic identification of biological molecules in a tissue or cellular sample without the need for further protein extraction. This method provides for studying cells or tissues by direct tissue MALDI (DT-MALDI), thereby substituting in situ protein release for further protein extraction. Mass/intensity data was processed with Mascot.COPYRGT. software interrogation of the NCBI database. These results are proof of principle that DT-MALDI, combined with bioinformatics, can directly identify proteins in cells and tissues from their mass spectra.
Inventor(s): Pevsner; Paul (New York, NY), Naftolin; Frederick (Woodbridge, CT), Miller; Douglas C. (Belle Mead, NJ), Hillman; Dean (New Hyde Park, NY), Stall; Brian K. (Bedford, NH), Wishnies; Steven M. (Columbia, MD)
Assignee: New York University (New York, NY)
Application Number:12/799,576
Patent Claims:1. A method for analyzing the biological molecule content of a tissue sample obtained from normal tissue or abnormal/diseased tissue in situ, wherein the method provides for a level of detection of the biological molecules in the sample in an amount ranging from about 1 attamol to about 10 attamols, comprising: a) collecting a sample of tissue from a subject into a first solution effective to maintain integrity of the biological molecule; b) treating the sample with a second solution comprising one or more enzymes, or chemicals, effective to dissociate the tissue sample or of digesting the dissociated tissue sample into smaller fragments; c) treating the preparation from step b) with a matrix assisted laser desorption ionization imaging (MALDI) matrix solution; d) analyzing the preparation from step c) by direct tissue (DT)-matrix assisted laser desorption ionization imaging (MALDI)-time of flight (TOF) measurement or DT-MALDI-TOF-TOF measurement; e) creating a data file utilizing the information from step d); f) entering the data from the data file of step e) into an external database to create a signature map for the tissue from which the data was obtained; and g) comparing the results from step d) with a signature map for normal tissue, wherein said normal tissue corresponds to, or is of the same tissue type, as the tissue from which the sample was obtained.

2. The method of claim 1, wherein the one or more enzymes effective to dissociate the tissue and degrading the tissue into peptide fragments are selected from the group consisting of a collagenase, a lipase and a protease.

3. The method of claim 1, wherein the time ranges from about 10 minutes to about 24 hours.

4. The method of claim 1, wherein the temperature ranges from about 20.degree. C. to about 60.degree. C.

5. The method of claim 1, wherein the MALDI matrix is selected from the group consisting of .alpha.-4 cyano hydroxy-cinnamic acid (CHCA), sinnapinic acid, p-nitroaniline, a heavy metal and glycerol.

6. The method of claim 1, wherein the diseased tissue is a tumor tissue, tissue from a hyperproliferative disorder other than cancer, or an ischemic tissue.

7. The method of claim 6, wherein the hyperproliferative disorder other than cancer is selected from the group consisting of rheumatoid arthritis, lupus, multiple sclerosis, psoriasis and other autoimmune diseases.

8. The method of claim 6, wherein the tumor tissue is obtained from a benign tumor or a malignant tumor.

9. The method of claim 6, wherein the ischemic tissue is obtained from the brain, spinal cord or other nervous system tissue.

10. The method of claim 6, wherein the ischemic tissue is obtained from the heart or intestinal tract.

11. The method of claim 1, wherein the normal or abnormal/diseased tissue is selected from the group consisting of solid tissue or non-solid tissue.

12. The method of claim 11, wherein the solid tissue is selected from the group consisting of nervous system tissue, cardiac tissue, breast tissue, lung tissue, bladder tissue, gastrointestinal tissue, eyes, bone and tissue from any solid tumor.

13. The method of claim 11, wherein the non-solid tissue is selected from the group consisting of whole blood or isolated blood cells.

14. The method of claim 13, wherein the isolated blood cells are red blood cells or white blood cells.

15. The method of claim 14, wherein the white blood cells are selected from the group consisting of lymphocytes, polymorphonuclear cells (PMNs), monocytes and macrophages.

16. A method for identifying the presence of abnormal or diseased tissue in a subject comprising: a) collecting at least two different tissue samples obtained from normal tissue or abnormal/diseased tissue, one of which is obtained from an area suspected of being diseased or abnormal and the second being normal tissue of the same tissue type; b) treating the tissue samples with a solution of one or more enzymes, or chemicals, effective to digest the tissue samples into smaller fragments; c) treating the preparation from step b) with a MALDI matrix solution; and d) analyzing the preparation from step c) by DT-MALDI-TOF measurement or DT-MALDI-TOF-TOF measurement, wherein the analyzing comprises comparing the biological molecule content of the at least two different tissue samples, and wherein the biological molecule content of the at least two different tissue samples is compared to a signature map for normal tissue or abnormal or diseased tissue of the same tissue type, wherein the signature map of the normal or diseased tissue is obtained from a pre-determined standard or from a known database of proteins isolated and characterized for that tissue and the specific disease of which the subject is suspected of having or at risk for developing.

17. A method for identifying the extent of tumor cell extravasation comprising: a) collecting two or more contiguous tissue samples obtained from normal tissue or abnormal/diseased tissue from a tumor mass and the surrounding tissue; b) treating the tissue samples with a solution of one or more enzymes, or chemicals, effective to digest the tissue samples into smaller fragments; c) treating the preparation from step b) with a MALDI matrix solution; and d) analyzing the preparation from step c) by DT-MALDI-TOF measurement or DT-MALDI-TOF-TOF measurement, wherein the analyzing comprises comparing the biological molecule content of the two or more contiguous tissue samples, wherein the biological molecule content of the two or more contiguous tissue samples is compared to a signature map for normal tissue or abnormal or diseased tissue of the same tissue type, wherein the signature map of the normal or diseased tissue is obtained from a pre-determined standard or from a known database of proteins isolated and characterized for that tissue and the specific disease of which the subject is suspected of having or at risk for developing.

Details for Patent 8,525,104

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial New York University (New York, NY) 2025-09-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Colorcon
Express Scripts
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.